Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors

   Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of
 Unknown Primary and Metastases of Known Primary Tumors Published in Clinical
                           Experimental Metastasis

PR Newswire

PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013

PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ -- Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced that data from a study
assessing the differences between cancer of unknown primary (CUP) and
metastatic solid tumors of known primary metastases (KPM) by profiling
microRNA expression were recently published in Clinical Experimental
Metastasis, in an article entitled "Global microRNA profiling in favorable
prognosis subgroups of cancer of unknown primary (CUP) demonstrates no
significant expression differences with metastases of matched known primary
tumors." The article can be viewed online at 

The study assessed microRNA differences between CUP metastases with favorable
prognosis and metastases of known primary tumors in order to screen for an
aggressive, pro-metastatic, CUP-specific biologic signature.

The study consisted of two stages. In the first stage, metastases obtained
from CUP cases were assigned to a primary tissue of origin using Rosetta's
miRview^® mets^2 microarray assay and compared to pathological and clinical
presentation. In the second stage, the expression of 733 microRNAs was
examined in CUP tumors classified as breast, serous ovarian and upper squamous
cancers and compared to that of matched KPMs.

The study evaluated approximately 100 CUP and KPM tumors and found no unique
microRNA signature differentiating CUP presentation from that of metastases of
known primaries. This supports current gold standard treatment for patients
with favorable prognosis CUP, who are managed similarly to those with
equivalent metastatic tumors of known primary. This study was a sub-set of a
larger retrospective study assessing the performance of the miRview mets^2
assay in a cohort of real CUP patients. The results of that study
demonstrated that miRview mets^2 assay showed agreement with pathological and
clinical information in 92% of cases. Those data have been presented at
medical conferences and are expected to be published in a separate
peer-reviewed journal article.

Study author, George Pentheroudakis, M.D., Department of Medical Oncology at
the University of Ioannina Medical School in Ioannina, Greece, noted, "This
research is the first look for microRNA characteristics of CUP tumors. Study
results confirmed epidemiologic evidence suggesting that patients with
favorable prognosis CUP have a presentation, response to therapy and outcome
no different from metastatic tumors of matched primaries."

"This publication demonstrates the utility of microRNA profiling in
understanding the biology of CUP and may have important implications for the
prognosis and treatment of CUP patients," stated Kenneth A. Berlin, President
and CEO of Rosetta Genomics. "We look forward to the publication of the full
data set which we believe continues to underscore the clinical value of our
miRview mets^2 assay in identifying the primary tumor type in CUP patients in
order to optimize treatment protocols and potentially improve clinical

About Cancer of Unknown Primary Origin

According to the American Cancer Society, an estimated 2 to 5 percent of all
cancer patients have metastatic (secondary) tumors for which routine testing
cannot locate the primary site. This is called cancer of unknown primary
origin. Patients may be diagnosed with cancer of unknown primary origin if the
primary tumor is too small to be identified with routine imaging tests, it
regresses (disappears) before a secondary tumor arises or the secondary tumor
has several possible primary sites. Cancer of unknown primary origin can
appear anywhere in the body, but is most commonly found in the lymph nodes,
liver, lungs, bones or skin.

The miRview mets^2 assay measures the expression level of 64 microRNA
biomarkers, which are then processed by an algorithm composed of two
classifiers and a decision-maker that can accurately identify the origin of
the patients' tumor for 42 different cancer tissue types, with 85 percent
sensitivity and 99 percent specificity. Clinicians use Rosetta Genomics' assay
to better diagnose CUP patients and get them on more optimal treatment plans.

About miRview^® Products

miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type
in primary and metastatic cancer including CUP. miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating to
Rosetta's strategic plan, the market acceptance of Rosetta's miRview^® assays,
particularly miRview^® mets^2, Rosetta's capitalization of its microRNA
platform and Rosetta's development of personalized medicine products
constitute forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta's Annual Report
on Form 20-F for the year ended December 31, 2011 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta's views only as of
the date of this release and should not be relied upon as representing its
views as of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.

Company Contact:              Investor Contacts:
Rosetta Genomics              LHA
Ken Berlin, President & CEO   Anne Marie Fields
(215) 382-9000, ext. 326      (212) 838-3777
                              Bruce Voss
                              (310) 691-7100

SOURCE Rosetta Genomics Ltd.
Press spacebar to pause and continue. Press esc to stop.